NOW WITH ~4-YEAR DATA VS IBRUTINIB*1

24-hour inhibition of BTK was maintained at 100% in PBMCs and 94% to 100% in lymph nodes when taken at the recommended total daily dose of 320 mg. The clinical significance of 100% inhibition has not been established.2,3

A BTK INHIBITOR THAT DELIVERS POWERFUL AND DURABLE RESPONSES AT ~4 YEARS IN WALDENSTRÖM’S MACROGLOBULINEMIA1-3

BRUKINSA VS IBRUTINIB: THE FIRST AND ONLY
HEAD-TO-HEAD TRIAL OF BTK INHIBITORS IN WM



*In an exploratory analysis, the median follow-up time was 44.4 months for Cohort 1 and 42.9 months for Cohort 2.


BTK=Bruton’s tyrosine kinase; NCCN®=National Comprehensive Cancer Network®; PBMCs=peripheral blood mononuclear cells; WM=Waldenström’s macroglobulinemia.

NCCN
Category 1
Preferred
Zanubrutinib (BRUKINSA®) is included as a Category 1 preferred treatment option for front-line and previously treated WM in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)4

Personalized patient support
dedicated to helping patients

A personalized and comprehensive support program designed
to help guide and assist patients, caregivers, and practices.

Simplifying
Access
Educating
Patients
Securing
Support

Healthcare professional resources

Find tools and education to help your practice

BTK inhibition

Brukinsa Difference
Established
Safety Profile
Safety
Flexible
Dosing
Dosing